CA3113654A1 - Methods of reversing ticagrelor activity - Google Patents
Methods of reversing ticagrelor activity Download PDFInfo
- Publication number
- CA3113654A1 CA3113654A1 CA3113654A CA3113654A CA3113654A1 CA 3113654 A1 CA3113654 A1 CA 3113654A1 CA 3113654 A CA3113654 A CA 3113654A CA 3113654 A CA3113654 A CA 3113654A CA 3113654 A1 CA3113654 A1 CA 3113654A1
- Authority
- CA
- Canada
- Prior art keywords
- ticagrelor
- seq
- hours
- patient
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39583—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials not provided for elsewhere, e.g. haptens, coenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862733892P | 2018-09-20 | 2018-09-20 | |
| US62/733,892 | 2018-09-20 | ||
| US201962806225P | 2019-02-15 | 2019-02-15 | |
| US62/806,225 | 2019-02-15 | ||
| US201962836373P | 2019-04-19 | 2019-04-19 | |
| US62/836,373 | 2019-04-19 | ||
| PCT/US2019/052173 WO2020061465A1 (en) | 2018-09-20 | 2019-09-20 | Methods of reversing ticagrelor activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3113654A1 true CA3113654A1 (en) | 2020-03-26 |
Family
ID=69887913
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3113654A Pending CA3113654A1 (en) | 2018-09-20 | 2019-09-20 | Methods of reversing ticagrelor activity |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20210347915A1 (https=) |
| EP (2) | EP4653465A3 (https=) |
| JP (2) | JP7478975B2 (https=) |
| KR (2) | KR20250161038A (https=) |
| CN (1) | CN113194821B (https=) |
| AU (1) | AU2019342755B2 (https=) |
| CA (1) | CA3113654A1 (https=) |
| DK (1) | DK3852617T3 (https=) |
| ES (1) | ES3042247T3 (https=) |
| FI (1) | FI3852617T3 (https=) |
| MX (1) | MX2021003298A (https=) |
| PL (1) | PL3852617T3 (https=) |
| WO (1) | WO2020061465A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106715473B (zh) | 2014-10-01 | 2021-11-23 | 免疫医疗有限公司 | 替格瑞洛的抗体及其使用方法 |
| PL3852617T3 (pl) * | 2018-09-20 | 2026-01-26 | SFJ Pharma X, Inc. | Zastosowanie fragmentów przeciwciała do odwrócenia aktywności tikagreloru |
| EP4337253A4 (en) * | 2021-05-10 | 2025-03-19 | Sfj Pharmaceuticals X, Ltd. | Pharmacokinetic & pharmacodynamic model for determining effective dose of anti-ticagrelor antibody |
| KR102952285B1 (ko) | 2021-07-13 | 2026-04-13 | 주식회사 엘지에너지솔루션 | 전지의 용접 상태 검사 방법 |
| US20260022197A1 (en) * | 2024-07-16 | 2026-01-22 | SFJ Pharma X, Inc. | Methods of reversing ticagrelor activity |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH03154867A (ja) * | 1989-11-13 | 1991-07-02 | Teijin Ltd | １―メチルアデノシンの免疫学的測定方法，そのための測定試薬及び試薬キット |
| MX2013014035A (es) * | 2011-06-01 | 2014-01-23 | Astrazeneca Ab | Nuevo co-cristal ticagrelor. |
| AU2013344796B2 (en) * | 2012-11-16 | 2016-11-10 | Novartis Ag | Use of IL-1 beta binding antibodies for treating peripheral arterial disease |
| KR20220041957A (ko) * | 2013-03-15 | 2022-04-01 | 아비에 도이치란트 게엠베하 운트 콤파니 카게 | 항-egfr 항체 약물 접합체 제형 |
| AU2014265624B2 (en) * | 2013-05-15 | 2019-09-12 | Medimmune Limited | Purification of recombinantly produced polypeptides |
| WO2016033424A1 (en) * | 2014-08-29 | 2016-03-03 | Genzyme Corporation | Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b |
| CN106715473B (zh) | 2014-10-01 | 2021-11-23 | 免疫医疗有限公司 | 替格瑞洛的抗体及其使用方法 |
| JP2018502894A (ja) * | 2015-01-27 | 2018-02-01 | アストラゼネカ アクチボラグ | 心筋梗塞の病歴がある患者においてアテローム血栓性イベントを治療または予防する方法 |
| KR101916956B1 (ko) * | 2016-12-13 | 2018-11-08 | 보령제약 주식회사 | 티카그렐러의 신규한 고체 형태 및 이의 제조방법 |
| CN110325211A (zh) * | 2016-12-23 | 2019-10-11 | 诺华股份有限公司 | 采用抗因子XI/XIa抗体治疗的方法 |
| BR112019018022A2 (pt) * | 2017-03-01 | 2020-06-02 | Medimmune Limited | Formulações de anticorpos monoclonais |
| PL3852617T3 (pl) * | 2018-09-20 | 2026-01-26 | SFJ Pharma X, Inc. | Zastosowanie fragmentów przeciwciała do odwrócenia aktywności tikagreloru |
-
2019
- 2019-09-20 PL PL19863329.9T patent/PL3852617T3/pl unknown
- 2019-09-20 EP EP25193499.8A patent/EP4653465A3/en active Pending
- 2019-09-20 KR KR1020257035868A patent/KR20250161038A/ko active Pending
- 2019-09-20 CN CN201980075991.0A patent/CN113194821B/zh active Active
- 2019-09-20 EP EP19863329.9A patent/EP3852617B1/en active Active
- 2019-09-20 JP JP2021515473A patent/JP7478975B2/ja active Active
- 2019-09-20 DK DK19863329.9T patent/DK3852617T3/da active
- 2019-09-20 US US17/278,075 patent/US20210347915A1/en active Pending
- 2019-09-20 MX MX2021003298A patent/MX2021003298A/es unknown
- 2019-09-20 KR KR1020217011614A patent/KR102880762B1/ko active Active
- 2019-09-20 CA CA3113654A patent/CA3113654A1/en active Pending
- 2019-09-20 AU AU2019342755A patent/AU2019342755B2/en active Active
- 2019-09-20 WO PCT/US2019/052173 patent/WO2020061465A1/en not_active Ceased
- 2019-09-20 ES ES19863329T patent/ES3042247T3/es active Active
- 2019-09-20 FI FIEP19863329.9T patent/FI3852617T3/fi active
-
2024
- 2024-04-09 JP JP2024062468A patent/JP2024096134A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ES3042247T3 (en) | 2025-11-19 |
| US20210347915A1 (en) | 2021-11-11 |
| WO2020061465A1 (en) | 2020-03-26 |
| EP3852617A1 (en) | 2021-07-28 |
| KR20210091698A (ko) | 2021-07-22 |
| JP2024096134A (ja) | 2024-07-12 |
| EP3852617B1 (en) | 2025-09-10 |
| KR20250161038A (ko) | 2025-11-14 |
| AU2019342755A1 (en) | 2021-05-06 |
| DK3852617T3 (da) | 2025-10-20 |
| EP4653465A2 (en) | 2025-11-26 |
| JP2022501368A (ja) | 2022-01-06 |
| JP7478975B2 (ja) | 2024-05-08 |
| MX2021003298A (es) | 2021-08-11 |
| KR102880762B1 (ko) | 2025-11-03 |
| EP4653465A3 (en) | 2026-01-07 |
| EP3852617A4 (en) | 2022-08-24 |
| FI3852617T3 (fi) | 2025-10-21 |
| CN113194821B (zh) | 2025-07-04 |
| PL3852617T3 (pl) | 2026-01-26 |
| CN113194821A (zh) | 2021-07-30 |
| AU2019342755B2 (en) | 2025-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3852617B1 (en) | Use of antibody fragments for reversing ticagrelor activity | |
| CA2994447C (en) | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack | |
| KR20190044673A (ko) | 응고 제 ix 인자 및/또는 활성화 응고 제 ix 인자 및 응고 제 x 인자 및/또는 활성화 응고 제 x 인자를 인식하는 이중특이성 항체의 사용법 | |
| JP2022512632A (ja) | 発作性夜間ヘモグロビン尿症（ｐｎｈ）の処置のための抗ｃ５抗体の皮下投薬及び投与 | |
| JP2026048712A (ja) | 第ＸＩ／ＸＩａ因子抗体の医薬製剤および投薬レジメン | |
| JP2022501368A5 (https=) | ||
| US20230192895A1 (en) | Pharmacokinetic & pharmacodynamic model for determining effective dose of anti-ticagrelor antibody | |
| KR20250107839A (ko) | 심혈관계 질환의 치료 방법 | |
| AU2017355613B2 (en) | Treatment regimens | |
| JP2025121902A (ja) | 治療用抗体製剤 | |
| US20200055942A1 (en) | Treatment regimens | |
| JPWO2020061465A5 (https=) | ||
| KR20230009431A (ko) | 발작성 야간 혈색소뇨증의 치료를 위한 보체 인자 d 저해제를 단독으로 또는 항-c5 항체와 조합한 용도 | |
| US20250025531A1 (en) | Extended, High Dose VEGF Antagonist Regimens for Treatment of Angiogenic Eye Disorders | |
| HK40119109A (en) | Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders | |
| EA050545B1 (ru) | Терапевтические составы антитела | |
| WO2021207667A1 (en) | Compositions and methods for treating lung injury or acute respiratory distress syndrome (ards) | |
| Musgrave | DOAC Reversal Agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220930 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240731 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240731 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240731 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20240802 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20240917 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250114 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250225 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250225 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250702 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250702 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20251020 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20260219 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260226 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260226 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260226 |